Clinical trial
Docetaxel and Ifosfamide in Treating Women With Metastatic Breast Cancer
NCT00026078 · Grupo Oncologico Cooperativo del Sur, Other · Unknown status
Key facts
| NCT number | NCT00026078 |
|---|---|
| Title | Docetaxel and Ifosfamide in Treating Women With Metastatic Breast Cancer |
| Official title | Docetaxel (DTX) - Ifosfamide (IFX) As First Line Chemotherapy In Metastatic Breast Cancer |
| Lead sponsor | Grupo Oncologico Cooperativo del Sur, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, ifosfamide |
| Enrollment | 42 |
| Start date | Mar 1, 2001 |
| First posted | Jan 27, 2003 |
| Last update posted | Aug 7, 2013 |
| Countries | Argentina, Mexico |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: